JAVIER
PUENTE VÁZQUEZ
Profesor asociado
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (3)
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45